Article info
PDFEpidemiology
Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease
- Correspondence to Professor Georg Schett, Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen 91054, Bayern, Germany; georg.schett{at}uk-erlangen.de
Citation
Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease
Publication history
- Received September 22, 2021
- Accepted October 19, 2021
- First published November 24, 2021.
Online issue publication
October 18, 2023
Article Versions
- Previous version (15 November 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage